Nutriband Inc
NTRB5.780USD
-0.440-7.07%
Close 11/04, 16:00（ET）Quotes delayed by 15 min
64.01MMarket Cap
LossP/E TTM
More Details of Nutriband Inc Company
Nutriband Inc. is engaged in the development of a portfolio of transdermal pharmaceutical products. Its development pipeline consists of transdermal products that are based on proprietary AVERSA abuse-deterrent transdermal technology. Its lead product under development is AVERSA Fentanyl, an abuse deterrent fentanyl transdermal system that combines an approved generic fentanyl patch with its AVERSA abuse deterrent transdermal technology to reduce the abuse and misuse of fentanyl patches. Its development pipeline also includes AVERSA Buprenorphine and AVERSA Methylphenidate. It is developing a portfolio of transdermal pharmaceutical products to deliver already approved drugs or biologics that are typically delivered by injection but with the potential to improve compliance and therapeutic outcomes through transdermal delivery. AVERSA technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
Nutriband Inc Info
Ticker SymbolNTRB
Company nameNutriband Inc
IPO dateJun 20, 2017
CEOMr. Serguei Melnik
Number of employees- -
Security typeOrdinary Share
Fiscal year-endJun 20
Address121 S Orange Ave Ste 1500
CityORLANDO
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code32801-3241
Phone14073776695
Websitehttps://nutriband.com/
Ticker SymbolNTRB
IPO dateJun 20, 2017
CEOMr. Serguei Melnik
Company Executives of Nutriband Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Serguei Melnik
Mr. Serguei Melnik
Chairman of the Board, President, Interim Chief Executive Officer, Secretary
Chairman of the Board, President, Interim Chief Executive Officer, Secretary
820.42K
--
Mr. Gerald Goodman
Mr. Gerald Goodman
Chief Financial Officer
Chief Financial Officer
86.33K
--
Dr. Jeff Patrick, Pharm.D.
Dr. Jeff Patrick, Pharm.D.
Chief Scientific Officer
Chief Scientific Officer
36.61K
--
Mr. Mark Hamilton
Mr. Mark Hamilton
Independent Director
Independent Director
17.21K
--
Mr. Radu Bujoreanu
Mr. Radu Bujoreanu
Independent Director
Independent Director
15.75K
--
Ms. Irina Gram
Ms. Irina Gram
Independent Director
Independent Director
1.17K
--
Mr. Sergei Glinka
Mr. Sergei Glinka
Independent Director
Independent Director
--
--
Prof. Dr. Stefani C. Mancas
Prof. Dr. Stefani C. Mancas
Independent Director
Independent Director
--
--
Dr. Alan Smith, Ph.D.
Dr. Alan Smith, Ph.D.
Chief Operating Officer, President of 4P Therapeutics
Chief Operating Officer, President of 4P Therapeutics
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Serguei Melnik
Mr. Serguei Melnik
Chairman of the Board, President, Interim Chief Executive Officer, Secretary
Chairman of the Board, President, Interim Chief Executive Officer, Secretary
820.42K
--
Mr. Gerald Goodman
Mr. Gerald Goodman
Chief Financial Officer
Chief Financial Officer
86.33K
--
Dr. Jeff Patrick, Pharm.D.
Dr. Jeff Patrick, Pharm.D.
Chief Scientific Officer
Chief Scientific Officer
36.61K
--
Mr. Mark Hamilton
Mr. Mark Hamilton
Independent Director
Independent Director
17.21K
--
Mr. Radu Bujoreanu
Mr. Radu Bujoreanu
Independent Director
Independent Director
15.75K
--
Ms. Irina Gram
Ms. Irina Gram
Independent Director
Independent Director
1.17K
--
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2026Q2
FY2026Q1
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Sale of goods
622.45K
0.00%
Services
0.00
0.00%
By RegionUSD
Name
Revenue
Proportion
United States
614.92K
98.79%
Non-United States
7.53K
1.21%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Sale of goods
622.45K
0.00%
Services
0.00
0.00%
Shareholding Stats
Updated: Tue, Aug 12
Updated: Tue, Aug 12
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Botgros (Vitalie)
25.65%
TII Jet Services, LDA
15.02%
Sheridan (Gareth)
14.64%
Glinka (Serguei)
6.86%
Melnik (Serguei)
6.82%
Other
31.01%
Shareholders
Shareholders
Proportion
Botgros (Vitalie)
25.65%
TII Jet Services, LDA
15.02%
Sheridan (Gareth)
14.64%
Glinka (Serguei)
6.86%
Melnik (Serguei)
6.82%
Other
31.01%
Shareholder Types
Shareholders
Proportion
Individual Investor
55.75%
Corporation
15.02%
Investment Advisor
2.02%
Investment Advisor/Hedge Fund
0.84%
Research Firm
0.03%
Other
26.33%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
36
347.57K
2.89%
-61.95K
2025Q2
44
8.87M
79.52%
+489.89K
2025Q1
43
8.13M
73.14%
+1.78M
2024Q4
40
8.04M
72.39%
+1.68M
2024Q3
40
8.08M
72.79%
+1.82M
2024Q2
38
5.19M
52.25%
+2.18M
2024Q1
34
4.36M
55.65%
+1.38M
2023Q4
30
4.30M
54.90%
+1.31M
2023Q3
29
2.96M
37.78%
-39.44K
2023Q2
28
2.95M
37.71%
-29.57K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Botgros (Vitalie)
3.09M
25.65%
--
--
Jun 20, 2025
TII Jet Services, LDA
1.81M
15.02%
+485.05K
+36.66%
Sep 01, 2024
Sheridan (Gareth)
1.76M
14.64%
--
--
Jun 20, 2025
Glinka (Serguei)
825.00K
6.86%
--
--
Jun 20, 2025
Melnik (Serguei)
820.42K
6.82%
--
--
Jun 20, 2025
The Vanguard Group, Inc.
199.63K
1.66%
+600.00
+0.30%
Jun 30, 2025
Goodman (Gerald)
86.33K
0.72%
--
--
Jun 20, 2025
Geode Capital Management, L.L.C.
63.63K
0.53%
+81.00
+0.13%
Jun 30, 2025
Smith (Allan)
41.91K
0.35%
--
--
Jun 20, 2025
Patrick (Jeff)
36.61K
0.3%
--
--
Jun 20, 2025
View more
Related ETFs
Updated: Sun, Nov 2
Updated: Sun, Nov 2
Name
Proportion
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Jul 29, 2022
Split
6→7
Date
Type
Ratio
Jul 29, 2022
Split
6→7
